

REMARKS

By this amendment, claim 1 is amended. Support can be found in the previous claim set. The amendment deletes a phrase whose antecedent was deleted in a previous amendment. Prompt issuance of a Notice of Allowance is respectfully requested. Claims 1, 6-12 and 38 are pending. Applicant respectfully submits that no issue of new matter arises.

Claim objection

The Advisory Action objected to claim 1 because of its recitation of “B_n is a chemical bond;”. Claim 1 is amended to delete this recitation in accordance with the Examiner’s suggestion. The antecedent component had been deleted. No issue of new matter arises. Reconsideration and withdrawal of this objection are respectfully requested.

Obviousness-type Double Patenting Rejection

A Terminal Disclaimer was filed June 18, 2009. However, US patent No. 7,202,059 mentioned in the March 19, 2009 Office Action at the penultimate paragraph of page 3 was not disclaimed. A Terminal Disclaimer is filed herewith, thereby obviating this rejection. Reconsideration and withdrawal of this rejection are respectfully requested.

Conclusion

In view of the above amendment and remarks, Applicant respectfully requests reconsideration and withdrawal of all pending objections and rejections. Applicant respectfully submits that the application is now in condition for allowance and request prompt issuance of a Notice of Allowance. Should the Examiner believe that anything further is desirable that might put the application in even better condition for allowance, the Examiner is requested to contact the undersigned at the telephone number listed below.

Fees

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

Respectfully submitted,

/George S. Jones/
George S. Jones, Reg. No. 38,508
Attorney for Applicant

sanofi aventis U.S. Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**3776**
Telefax (908) 231-2626

sanofi aventis Docket No. DEAV2001/0007 US NP